Considering Drug-Drug Interactions When Selecting a First-line Antiretroviral Therapy for a Patient With a Complex Medical History

Faculty: Charles W. Flexner, MD Paul Pham, PharmD, BCPS CREDIT INFORMATION Release Date: 05/15/09 Expiration Date: 05/14/10 Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Status: Please log in to view status

Charles W. Flexner, MD, and Paul Pham, PharmD, BCPS, coauthor a case vignette that describes the management of a patient with a medical history and multiple nonantiretroviral medications that increase the potential for drug-drug interactions. Learning Objectives Upon completion of this activity, participants should be able to: Describe necessary dose adjustments when combining efavirenz and atazanavir/ritonavir Discuss the results of the ACTG 5142 study in regards to the use of NRTI-sparing regimen, lopinavir/ritonavir and efavirenz Summarize the pharmacokinetic differences of using once-daily vs twice-daily darunavir/ritonavir when combined with efavirenz Abstract Click here to view abstract

Does Polypharmacy Increase the Likelihood of Renal Toxicity Among Persons With HIV?

Faculty: Lynda Szczech, MD, MSCE, FASN CREDIT INFORMATION Release Date: 06/25/09 Expiration Date: 06/24/10 Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Status: Please log in to view status

In this CME-certified Case Vignette, Lynda Szczech, MD, MSCE, FASN, discusses the management of an HIV–infected patient with diabetic nephropathy and heart failure who is being treated with multiple medications in addition to antiretrovirals. Learning Objectives Upon completion of this activity, participants should be able to: Describe the frequency of acute kidney injury in patients taking a tenofovir-containing antiretroviral regimen Identify medications associated with increased risk of acute kidney injury List the factors that may contribute to the risk of renal toxicity in patients on antiretroviral therapy Abstract Click here to view abstract

Management of a Patient Receiving an Initial Atazanavir/Ritonavir-Based Regimen With a Helicobacter Pylori Infection

Faculty: Ian McNicholl, PharmD, BCPS (AQ-Infectious Diseases), AAHIVE CREDIT INFORMATION Release Date: 08/27/09 Expiration Date: 08/26/10 Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Status: Please log in to view status

Ian McNicholl, PharmD, BCPS, describes the pharmacologic considerations of treating a Helicobacter pylori infection in an HIV-infected patient with dyslipidemia receiving an initial atazanavir/ritonavir-based regimen. Learning Objectives Upon completion of this activity, participants should be able to: Describe pharmacokinetic interactions between atazanavir and proton pump inhibitors Explain how combining PIs and pravastatin may affect pravastatin pharmacokinetics Cite expert recommendations for treating a Helicobacter pylori infection Abstract Click here to view abstract

Drug-Drug Interactions Tool

Faculty:   Charles W. Flexner, MD Paul Pham, PharmD, BCPS This interactive tool will enable readers to select a specific antiretroviral agent from a listing of all FDA-approved agents, and either: Display and print a report of the interactions between this drug and other antiretroviral agents and commonly prescribed concomitant medications, or Select multiple concomitant agents from a listing of those most commonly used by HIV-infected patients, and create a report on any interactions between the selected antiretroviral agents and other non-antiretroviral medications. Data last updated October 1, 2009. Format: Adobe Flash (.swf) | File size: 134 KB

Drug-Drug Interactions in HIV-Infected Patients: A Downloadable Tool for Mobile Devices

This unique downloadable tool for Palm and Pocket PC/Windows Mobile handheld devices allows you to:

Tool Version 1.2.  Data last updated October 1, 2009.

Download to Hand-held Devices

DOWNLOADABLE FORMATS

Pocket PC / Windows Mobile executable Format: Pocket PC | File size: 14.79 MB Device Compatibility Pocket PC 2003/Windows Mobile 5 Touchscreen required 3.7 MB available memory PC Compatibility Windows 2000 or later Microsoft ActiveSync Instructions Connect device to PC and start ActiveSync Download EXE to PC Run EXE and follow onscreen instructions

Pocket PC / Windows Mobile zipped file Format: Pocket PC | File size: 2.82 MB Connect device to PC and start ActiveSync Download zip file to PC Extract files Run EXE file

Palm OS executable Format: Palm | File size: 3.81 MB Device Compatibility Color Palm, minimum resolution 320x320 (Zire devices not supported) Palm OS 4 or later 3.7 MB available memory PC Compatibility Windows 2000 or later Palm Desktop Instructions: Connect device to PC and start Palm Desktop Download EXE to PC Run EXE HotSync the device

Palm OS zipped file Format: Palm | File size: 781 KB Connect device to PC and start Palm Desktop Download zip file to PC Extract files Run EXE file HotSync the device